Archive | Funding Opportunities RSS for this section

NEW⇒C17 Operating and Ewing Sarcoma Grant Competition. Registration due 08-Sep-17. Grants due 29-Sep-17. All areas of research welcome. Spread the word!!

C17 is pleased to announce a SUPPLEMENTAL GRANT COMPETITION for both the C17 Research Network Operating Grant Competition (Round 20) and the Ewing Sarcoma Grant Competition (Round 5). This competition does not replace the regular fall competition.  It is an additional funding opportunity.

The C17 operating grant competition is focused on multicenter, multidisciplinary pediatric oncology/hematology research. The Ewing Sarcoma Competition is focused on research with a direct application into the causes, treatment, cure and quality of life for young people with Ewing Sarcoma.

Forms and documents can be found attached as linked above, and can be downloaded from www.c17.ca/council-and-administrators/research/ under Committees> Research Network.

If you have any questions, please contact the C17 Research Network Coordinator, Leah C. Young, Ph.D.  leah.young2 (at) ahs.ca

Alex’s Lemonade Stand “Reach Grant” (preclinical focus, $250,000/2yrs) and “A Award” (early career support, $800,000/4yrs) applications due May 22, 2017

‘A’ Award Program Goals

www.alexslemonade.org/sites/default/files/2017_a-award_guidelines_final.pdf

  • To encourage the best and brightest early career independent researchers to build lifelong careers and become leaders in the field of pediatric cancer research.
  • To advance research that will lead to new treatments and cures impacting children with cancer.
  • Initial Awards are for $800,000 over 4 years (no more than $200,000 in any given year).
  • Funds must be granted to non-profit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.

Reach Grants

www.alexslemonade.org/sites/default/files/2017_reach_guidelines_final.pdf

  • To support important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial; selected late translational studies.
  • Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.
  • Maximum of $125,000 in total costs may be requested per year.
  • Funds must be granted to non-profit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.

Survivorship and Palliative End-of-Life CCRA Research Frameworks released March 2017

The CCRA research frameworks were developed to guide Canada’s cancer research funders in their response to the recommendations in Target 2020, CCRA’s current strategic plan. Their intent is to identify research priorities to enable coordinated action among CCRA members, other funders, and key stakeholders with the goal of optimizing the excellence, relevancy, and impact of cancer research in Canada.

The Pan-Canadian Frameworks for Cancer Survivorship Research and Palliative and End-of-Life Care Research are now available through the CCRA website.

English

www.ccra-acrc.ca/index.php/publications-en/strategy-related-publications

Français

www.ccra-acrc.ca/index.php/fr/publications-fr/strategie-publications-connexes

CCSRI – change of deadline dates for upcoming competitions

CCSRI announced their upcoming competition deadlines, and included the note that some dates have changed. Details will be made available shortly for the following:
  • Knowledge to Action grants (abstract registration deadline April 1; funding start November 1, 2017)
  • Impact grants (letter of intent deadline April 3; funding start February 1, 2018)
  • Innovation grants with a focus only on prevention  (abstract registration deadline May 1; funding start November 1, 2017)
  • Quality of Life grants (letter of intent deadline May 15; funding start February 1, 2018)

Visit the CCSRI website for information: www.cancer.ca/research

 

Are you following CAR-T and other immunotherapy research in Canada? BioCanRx has announced $11 million investment in 16 collaborative research projects in novel therapies to cure cancer, including funding to manufacture the first made-in-Canada CAR-T cells.

OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET – BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer, including research aimed at developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada.

BioCanRx is investing in research projects advancing several innovative engineered T cell designs, which will further benefit from this infrastructure and capacity investment, and accelerate delivery of these novel concepts into clinical testing in Canada. This Canadian capacity development will pave the way to enable Canadian patients to access this new technology, and will give Canadian researchers the necessary resources to deliver on their innovations in CAR-T and other engineered T cell platforms. This CAR-T manufacturing initiative is unique in that the Canadian academic community recognized a gap and stepped up to drive Canadian solutions to meet grassroots efforts taking place in the U.S., China and Europe.

To help ensure CAR-T cell therapy is brought to patients safely and effectively, BioCanRx is funding a companion Clinical, Social, and Economic Impact project. It will review the existing base of knowledge and involve patient consultation to design a rigorous CAR-T clinical trial protocol ready to implement once the products are ready for a phase 1 clinical trial.

Do you know a promising PostDoc who is ready to launch their career? CRS has launched a $160,000 Next Generation of Scientists Competition. (due April 28)

The Cancer Research Society is pleased to announce the launch its 2017 Scholarships for the Next Generation of Scientists competition, an initiative aiming at supporting future generations of Canadian researchers. The Scholarship is broken down into two parts, and extends over a period of 3 years, with no possibility for renewal.

Deadlines for submitting an application: April 28, 2017, 11:59 pm (EST).

Part 1: Postdoctoral Salary Award –  1 year* –  $40,000

One year postdoctoral salary award for a candidate finishing his/her fellowship. The candidate must have completed at least two years of postdoctoral training at the time he/she accepts the salary award.
* Possibility of extending Part 1 of this award for a maximum period of 6 months.

Part 2: Operating Grant  –   2 years – $120,000 ($60,000/year)

Operating grant award once the candidate has obtained a faculty position at a recognized Canadian institution.

For details and application instructions go to:  www.crs-src.ca/Scholarships_Next_Generation_Scientists

C17 Research Network call for LOI: Operating Grants and Ewing Sarcoma Grant (LOI due December 16)

C17 is pleased to announce Round 19 of the C17 Research Network Operating Grant Competition and Round 4 of the Ewing Sarcoma Grant Competition (2016/17). The submission deadline for C17 LOIs is December 16, 2016 at 4pm MST.

The C17 operating grant competition is focused on multicenter, multidisciplinary pediatric oncology/hematology research.

The Ewing Sarcoma Competition is focused on research with a direct application into the causes, treatment, cure and quality of life for young people with Ewing Sarcoma.

The full call for LOI, application form and guidance document can be found at the links below and can be downloaded from the C17 website www.c17.ca/council-and-administrators/research/ (under Committees> Research Network).

In addition, C17 has partnered with the Cancer Research Society (CRS) to fund up to one grant in the area of pediatric oncology research. Applications focusing on basic/translational research or pre-clinical developmental therapeutics (DVL) should be directed towards this competition, anticipated announcement November 7, 2016.

For more information about the CRS competition, forms and deadlines go to: hwww.crs-src.ca/for-researchers-operating-grant

C17 Research Network call for the 2016/17 Operating Grant and Ewing Sarcoma competitions to be announced October 26

Watch for the following on OCTOBER 26:

  • The official call for the C17 Research Network Grant Competition announced through Sosido
  • Current/past researchers and those on the Research Network mailing list will receive the call through email
  • The updated application form and the award guide will be uploaded to http://www.C17.ca

Travel conference funds for non-MD Canadian health care professionals: 2016 17 Norma Auger Education Fund applications due November 1

Application form: 2016 Norma Auger Application

The goal of the C17 Norma Auger Education Fund is to support health professionals involved in pediatric Oncology/Hematology/BMT across Canada advance their knowledge, skills and experience and to promote presentations and knowledge translation by these health professionals.  This is an annual scholarship offered by the C17 Education Committee with funding from the Childhood Cancer Canada Foundation and the Coast to Coast Against Cancer Foundation.

Eligibility:  Non-MD Pediatric Oncology/Hematology/BMT health care professionals working in Canada.

Application deadline:  Tuesday, November 1, 2016.

Selection Process: Applications will be reviewed by the C17 Education Committee.  Successful applicants will be notified in writing.

Good news for patients, researchers, and health care decision makers – CIHR Launches the SPOR Innovative Clinical Trials Initiative

 

See link for more information:  http://www.cihr-irsc.gc.ca/e/49773.html

The first funding opportunities under this initiative will provide funding for

  • catalyst grants
  • multi-year grants, and
  • mentorship Chairs (launched on July 28, 2016).

If you have any questions,  contact  spor-srap@cihr-irsc.gc.ca